GoodRx Reports Q1 2026 Earnings with Mixed Revenue Performance
In its Q1 2026 earnings call, GoodRx reported total revenue of $194 million. Pharma Direct and Subscription revenues showed strong growth at 82% and 16%, respectively, while Prescription Transactions Revenue declined by 24%. The company highlighted direct retail pharmacy contracts with nine of the top ten pharmacies in the U.S.
Tickers: $GDRX